Romita has over 15 years of experience in health economics and outcomes research, specializing in rare diseases and challenging HTA submissions. She has worked across a wide range of therapy areas, delivering national market access solutions for major pharmaceutical companies like AstraZeneca and Merck Sharp & Dohme.
Before joining FIECON, Romita led submissions to Health Technology Assessment bodies in the UK and contributed to evidence generation and value proportion tool development. She was also a committee member of the All Wales Medicines Strategy Group (AWMSG)’s New Medicine Group from 2014 to 2017.
Romita holds a Master’s (with Distinction) in Economic Evaluation in Healthcare from City University London and a BA (Honours) in Natural Sciences from the University of Cambridge.
Delivered successful submissions to HTA bodies, including value proportion tool development.
Extensive expertise in rare diseases and challenging HTA submissions
Committee member at AWMSG
Part of the New Medicine Group between 2014 and 2017.
Published in fields of cost-effectiveness modelling, indirect treatment comparison, and RWE studies
Experience in range of therapy areas:
Rare diseases
Cardiovascular disease
Infectious diseases
Diabetes
Gastrointestinal disease
Osteoporosis
Mental health
FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”
Senior Market Access Manager, Mid-sized Pharma
It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”
Associate Director, Mid-sized Pharma
FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”
Market Access Director, Small Biotech
FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”
Disease Area Director, Big Pharma
The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation. ”
Executive Director, Biotech
FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”
Value Demonstration & Access Lead, Big Pharma
It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”
Senior Vice President, Small Biotech
FIECON’s team is highly experienced, commercially focused, responsive and flexible. A particular strength I highlight is that FIECON’s team becomes a true partner with all company functions that they interact with. ”
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts. More info
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts.
